Title:
METHOD FOR PREDICTING SUSCEPTIBILITY OF CANCER TO PARP INHIBITORS, AND METHOD FOR DETECTING CANCER HAVING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY
Document Type and Number:
WIPO Patent Application WO/2020/137076
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a method for predicting the susceptibility of a target cancer to PARP inhibitors. The present invention provides a method for predicting the susceptibility of a cancer to PARP inhibitors. The method includes a step for creating a mutation catalog by performing a sequence analysis on nucleic acid samples obtained from cancer cells. The presence of a cancer that is susceptible to PARP inhibitors is indicated by the contribution of BRCA signatures to the mutation catalog being greater than the contribution of Age signatures to the mutation catalog and by an absence of cyclin E1 amplification.
Inventors:
ODA KATSUTOSHI (JP)
ABURATANI HIROYUKI (JP)
YAMAMOTO SHOGO (JP)
HASEGAWA KOSEI (JP)
ABURATANI HIROYUKI (JP)
YAMAMOTO SHOGO (JP)
HASEGAWA KOSEI (JP)
Application Number:
PCT/JP2019/039415
Publication Date:
July 02, 2020
Filing Date:
October 04, 2019
Export Citation:
Assignee:
UNIV TOKYO (JP)
UNIV SAITAMA MEDICAL (JP)
UNIV SAITAMA MEDICAL (JP)
International Classes:
C12Q1/6869; A61K45/00; A61P35/00
Foreign References:
| JP2016523511A | 2016-08-12 |
Other References:
HODGSON DARREN R; DOUGHERTY BRIAN A; LAI ZHONGWU; FIELDING ANITRA; GRINSTED LYNDA; SPENCER STUART; O’CONNOR MARK J; HO TONY W; ROB: "Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes", BRITISH JOURNAL OF CANCER, vol. 119, no. 11, 24 October 2018 (2018-10-24), pages 1401 - 1409, XP036871225
STRONACH E.A. ET AL.: "Biomarker assessment of HR deficiency, tumor BRCA1/2mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy", MOL. CANCER RES., vol. 16, no. 7, July 2018 (2018-07-01), pages 1103 - 1111, XP055539341, DOI: 10.1158/1541-7786.MCR-18-0034
ODA, KATSUTOSHI ET AL.: "Non-official translation: A multi-center, phase II study of Olaparib (a PARP inhibitor) maintenance therapy in primary ovarian cancer patients, using an exome sequencing-based biomarker for homologous recombination deficiency", ABSTRACTS FOR THE 56TH ANNUAL MEETING OF JAPAN SOCIETY OF CLINICAL ONCOLOGY, October 2018 (2018-10-01)
STRONACH E.A. ET AL.: "Biomarker assessment of HR deficiency, tumor BRCA1/2mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy", MOL. CANCER RES., vol. 16, no. 7, July 2018 (2018-07-01), pages 1103 - 1111, XP055539341, DOI: 10.1158/1541-7786.MCR-18-0034
ODA, KATSUTOSHI ET AL.: "Non-official translation: A multi-center, phase II study of Olaparib (a PARP inhibitor) maintenance therapy in primary ovarian cancer patients, using an exome sequencing-based biomarker for homologous recombination deficiency", ABSTRACTS FOR THE 56TH ANNUAL MEETING OF JAPAN SOCIETY OF CLINICAL ONCOLOGY, October 2018 (2018-10-01)
Attorney, Agent or Firm:
YOKOTA Nobutaka et al. (JP)
Download PDF: